Nejrizikovější faktory pro vznik pankreatitidy po ERCP – systematický přehled zaměřený na prevenci

Stáhnout PDF English version

Autoři: G. R. Sivandzadeh ¹; S. A. Taghavi ²; F. Ejtehadi ³; R. Niknam ⁴; M. Tahani ⁵; S. Rakhshaninasab ⁵; I. Shahramian ⁶
Působiště autorů: Department of Internal Medicine, School of Medicine, Gastroenterohepatology Research Center, Internal Medicine Research Institute, Shiraz University of Medical Sciences. ¹; Department of Internal Medicine, School of Medicine, Gastroenterohepatology Research Center, Internal Medicine Research Institute, Shiraz University of Medical Sciences. ²; Department of Internal Medicine, School of Medicine, Gastroenterohepatology Research Center, Internal Medicine Research Institute, Namazi Teaching Hospital, Shiraz University of Medical Sciences. ³; Department of Internal Medicine, School of Medicine, Namazi Teaching Hospital, Abu Ali Sina for Medicine & Organ Transplant, Shiraz University of Medical Sciences. ⁴; Pediatric Gastroenterology and Hepatology Research Center, Zabol University of Medical Sciences, Zabol, Iran. ⁵; Department of Pediatrics, School of Medicine, Namazi Teaching Hospital, Abu Ali Sina for Medicine & Organ Transplant, Shiraz University of Medical Sciences. ⁶
Vyšlo v časopise: Gastroent Hepatol 2024; 78(4): 345-351
Kategorie: Digestivní endoskopie: přehledová práce
doi: https://doi.org/10.48095/ccgh2024345

Souhrn

Pankreatitida po endoskopické retrográdní cholangiopankreatografii (ERCP) je nejčastější a nejnebezpečnější komplikací diagnostické a terapeutické ERCP. Pro identifikaci rizikových pacientů a následný výběr vhodného alternativního způsobu diagnostiky je potřeba provést multifaktoriální studii rizikových faktorů vzniku PEP. Taková studie byla provedena. Dva nezávislí výzkumníci (MT, SH R) hledali relevantní studie publikované mezi 1/1/2017 a 1/10/2022. Literaturu v anglickém jazyce prohledali pomocí MEDLINE přes PubMed, EMBASETM přes Ovid, the Cochrane Library a Trip. V jiných jazycích hledali přes Magiran, SID, KoreaMed a LILACS. Hledaný termín byl endoskopická retrográdní cholangiopankreatografie NEBO pankreatitida NEBO rizikové factory NEBO ERCP NEBO systematický přehled. Vybráno bylo 174 studií. Pět z nich splňovalo požadovaná kritéria a byly definitivně vybrány. Tento článek prezentuje současné znalosti o nejrizikovějších faktorech pro vznik post--ERCP pankreatitidy, která je nejčastější komplikací ERCP. Panuje debata o patofyziologii PEP. Díky její komplexitě by prevence PEP měla zahrnovat úvahu o různých predisponujících faktorech, jako rizikovost pacientů, farmakologická profylaxe a metodou provedení. Věk, pohlaví a předchozí pozitivní anamnéza nemoci patří mezi nejrizikovější faktory pro vznik pankreatitidy po ERCP.

Klíčová slova:

pankreatitida – endoskopická retrográdní cholangiopankreatografie – rizikové factory – ERCP – PEP –přehled

Zdroje

1. Alomari M, Al Momani L, Alomari A et al. The Incidence of Endoscopic Retrograde Cholangiopancreatography-Related Complications in Patients with Liver Transplant: A Meta-Analysis and Systematic Review. Gastroenterology Res 2021; 14 (5): 259–267. doi: 10.14740/gr1391.

2. Park JS, Kim MH, Lee SK et al. Efficacy of endoscopic and percutaneous treatments for biliary complications after cadaveric and living donor liver transplantation. Gastroint endosc 2003; 57 (1): 78–85. doi: 10.1067/mge.2003.11.

3. Ostroff JW. Post-transplant biliary problems. Gastroint Endosc Clin N Am 2001; 11 (1): 163–183.

4. Boeva I, Karagyozov PI, Tishkov I. Post-liver transplant biliary complications: Current knowledge and therapeutic advances. World J Hepatol 2021; 13 (1): 66–79. doi: 10.4254/wjh.v13.i1.66.

5. Mosca S, Militerno G, Guardascione MA et al. Late biliary tract complications after or thotopic liver transplantation: diagnostic and therapeutic role of endoscopic retrograde cholangiopancreatography. J Gastroenterol He -patol 2000; 15 (6): 654–660. doi: 10.1046/j.1440-1746.2000.02198.x.

6. Sharma S, Gurakar A, Jabbour N. Biliary strictures following liver transplantation: past, present and preventive strategies. Liver Transplant 2008; 14 (6): 759–769. doi: 10.1002/lt.21509.

7. Balderramo D, Bordas JM, Sendino O et al. Complications after ERCP in liver transplant recipients. Gastrointestinal endoscopy. Gastrointest Endosc 2011; 74 (2): 285–294. doi: 10.1016/j.gie.2011.04.025.

8. Moy BT, Birk JW. A review on the management of biliary complications after orthotopic liver transplantation. J Clin Transl Hepatol. 2019 Mar 28; 7 (1): 61–71. doi: 10.14218/JCTH.2018.00028.

9. Sanada Y, Katano T, Hirata Y et al. Biliary complications following pediatric living donor liver transplantation: risk factors, treatments, and prognosis. Transplantation 2019; 103 (9): 1863–1870. doi: 10.1097/TP.0000000000002 572.

10. Ahmad DS, Faulx A. Management of postcholecystectomy biliary complications: a narrative review. Am J Gastroenterol 2020; 115 (8): 1191–1198. doi: 10.14309/ajg.0000000000000704.

11. Tryliskyy Y, Bryce GJ. Post-ERCP pan creatitis: pathophysiology, early identification, and risk stratification. Adv Clin Exp Med 2018; 27 (1): 149–154. doi: 10.17219/acem/66773.

12. Parekh PJ, Majithia R, Sikka SK et al. The “Scope” of post-ERCP pancreatitis. Mayo Clin Proc 2017; 92 (3): 434–448. doi: 10.1016/j.mayocp.2016.10.028.

13. Mine T, Morizane T, Kawaguchi Y et al. Clinical practice guideline for post-ERCP pancreatitis. J Gastroenterol 2017; 52 (9): 1013–1022. doi: 10.1007/s00535-017-1359-5.

14. Morales SJ, Sampath K, Gardner TB. A review of prevention of post-ERCP pancreatitis. Gastroenterol hepatol 2018; 14 (5): 286–292.

15. Nunnelee JD, Musselman R, Spaner SD. Appendectomy in pregnancy and postpartum: analysis of data from a large private hospital. Clin Excell Nurse Pract 1999; 3 (5): 298–301.

16. Freeman ML. Complications of endoscopic biliary sphincterotomy: a review. Endoscopy. 1997; 29 (4): 288–297. doi: 10.1055/s-2007-1004193.

17. Freeman ML, DiSario JA, Nelson DB et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54 (4): 425–434. doi: 10.1067/mge.2001.117550.

18. Loperfido S, Angelini G, Benedetti G et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998; 48 (1): 1–10. doi: 10.1016/s0016-5107 (98) 70121-x.

19. Masci E, Toti G, Mariani A et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 200; 96 (2): 417–423. doi: 10.1111/j.1572-0241. 2001.03594.x.

20. Vandervoort J, Soetikno RM, Tham TC et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc 2002; 56 (5): 652–656. doi: 10.1067/mge.2002.129086.

21. Cheng CL, Sherman S, Watkins JL et al. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. Am J Gastroenterol 2006; 101 (1): 139–147. doi: 10.1111/j.1572-0241.2006.00380.x.

22. Li GZ, Wang F, Fang J et al. Risk factors for post-endoscopic retrograde cholangiopancreatography pancreatitis: evidence from 1 786 cases. Med Sci Monit 2018; 24 : 8544–8552. doi: 10.12659/MSM.913314.

23. Lin Y, Liu X, Cao DQ et al. Analysis of risk factors and prevention strategies of post-ERCP pancreatitis. Eur Rev Med Pharmacol Sci 2017; 21 (22): 5185–5190. doi: 10.26355/eur rev_201711_13838.

24. Syrén E, Eriksson S, Enochsson L et al. Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography. BJS open 2019; 3 (4): 485–489. doi: 10.1002/bjs5.50162.

25. Dumonceau JM, Andriulli A, Elmunzer BJ et al. European Society of Gastrointestinal Endoscopy. Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) guideline –⁠ updated June 2014. Endoscopy 2014; 46 (9): 799–815. doi: 10.1055/s-0034-1377875.

26. Cotton PB, Lehman G, Vennes J et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37 : 383–393. doi: 10.1016/s0016-5107 (91) 70740-2.

27. Freeman ML. Post-ERCP pancreatitis: patientand technique-related risk factors. JOP 2002; 3 (6): 169–176.

28. Pezzilli R, Romboli E, Campana D et al. Mechanisms involved in the onset of post-ERCP pancreatitis. JOP 2002; 3 (6): 162–168.

29. Chen JJ, Wang XM, Liu XQ et al. Risk factors for post-ERCP pancreatitis: asystematic review of clinical trials with a large sample size in the past 10 years. Eur J Med Res 2014; 19 (1): 26.

30. Albai O, Roman D, Frandes M. Hypertriglyceridemia, an important and independent risk factor for acute pancreatitis in patients with type 2 diabetes mellitus. Ther Clin Risk Manag 2017; 13 : 515–522. doi: 10.2147/TCRM.S134560.

31. Fortson MR, Freedman SN, Webster PD 3rd. Clinical assessment of hyperlipidemic pan creatitis. Am J Gastroenterol 1995; 90 : 2134––2139.

32. Adler DG, Haseeb A, Francis G et al. Efficacy and safety of therapeuticERCP in patients with cirrhosis: a large multicenter study. Gastrointest Endosc 2016; 83 (2): 353–359. doi: 10.1016/j.gie.2015.08.022.

33. Navaneethan U, Njei B, Zhu X et al. Safety of ERCP in patients with liver cirrhosis: a national database study. Endosc Int Open 2017; 5 (4): E303–E314. doi: 10.1055/s-0043-102492.

34. Noel RA, Braun DK, Patterson RE et al. Increased risk of acute pancreatitis and biliary diseaseobserved in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009; 32 (5): 834–838. doi: 10.2337/dc08-1755.

35. Shen HN, Lu CL, Li CY. Effect of diabetes on severity and hospital mortality in patients with acute pancreatitis: a national population-based study. Diabetes Care 2012; 35 (5): 1061–1066. doi: 10.2337/dc11-1925.

36. Zhao ZH, Hu LH, Ren HB et al. Incidence and risk factors for post-ERCP pancreatitis in chronic pancreatitis. Gastroint Endosc 2017; 86 (3): 519–524. doi: 10.1016/j.gie.2016.12.020.

37. Ilone S, Fauzi A. Diagnostic and prevention approach in post endoscopic retrograde cholangiopancreatography pancreatitis. Ind J Gastroenterol Hepatol Dig Endosc 2017; 17 (3): 188–193.

38. Elmunzer BJ. Reducing the risk of post‐endoscopic retrograde cholangiopancreatography pancreatitis. Dig Endosc 2017; 29 (7): 749–757. doi: 10.1111/den.12908.

39. Morales SJ, Sampath K, Gardner TB. A review of prevention of post-ERCP pancreatitis. Gastroenterol Hepatol (NY) 2018; 14 (5): 286–292.

40. Esmailzadeh A, Bagheri HH, Pakdaman SM et al. The effect of diclofenac suppository on the occurrence of pancreatitis and the presence of shunt after ERCP in patients with ductal stones. Journal of the Faculty of Medicine, Mashhad University of Medical Sciences. 2015; 58 (9): 505–515.

41. Sotoudehmanesh R, Ali-Asgari A, Khatibian M et al. Pharmacological prophylaxis versus pancreatic duct stenting plus pharmacological prophylaxis for prevention of post-ERCP pancreatitis in high risk patients: a randomized trial. Endoscopy. 2019; 51 (10): 915–921. doi: 10.1055/a-0977-3119.

42. Cheon YK. Can postendoscopic retrograde cholangiopancreatography pancreatitis be prevented by a pharmacological approach? Korean J Intern Med 2013; 28 (2): 141–148. doi: 10.3904/kjim.2013.28.2.141.

43. Ting PH, Luo JC, Lee KC et al. Post endoscopic retrograde cholangiopancreatography cholecystitis: the incidence and risk analysis. J Chin Med Assoc 2020; 83 (8): 733–736. doi: 10.1097/JCMA.0000000000000383.

Abbreviations

ERCP –⁠ endoscopic retrograde cholangiopancreatography

OLT –⁠ orthotopic liver transplant

PEP –⁠ post-ERCP pancreatitis

ORCID authors

G. H. Sivandzadeh 0000-0001-5461-5754,

S. A. Taghavi 0000-0001-5360-6776,

F. Ejtehadi 0000-0002-0791-0133,

R. Niknam 0000-0002-2608-8018,

M. Tahani 0000-0002-0213-9087,

S. Rakhshaninasab 0000-0002-6809-175X,

I. Shahramian 0000-0002-4134-1405.